Ho Cho, Ph.D.
Ho Sung Cho, Ph.D., is a protein medicinal chemist with over 28 years of experience in recombinant protein design, expression, purification, modification, and analysis. He currently serves as Senior Vice President of Discovery Biotherapeutics at Bristol-Meyers Squibb (BMS). Before BMS’s acquisition of Celgene, he was Corporate Vice President of Biotherapeutics at Celgene. Since joining Celgene in 2014, Dr. Cho has served in a leadership role focused on integrating internal and external capabilities and programs to deliver transformative medicines based on recombinant DNA technologies. Dr. Cho is also the site head for BMS San Diego and serves on the leadership team for Research & Early Development. Prior to joining Celgene, Dr. Cho served as the Chief Technology Officer at Ambrx.
Prior to joining industry, Dr. Cho worked on the structural genomics project at the Lawrence Berkeley National Labs. He received his Ph.D. in Chemistry from the University of California, Berkeley and a B.S. in Chemistry from North Carolina State University.